Abstract
This study focuses on understanding the structural features of 3,6-dihydroimidazo(4,5-d)pyrrolo(2,3-b)pyridin-2(1H)-one (dpp) derivatives to computationally identify new JAK inhibiting compounds. For the purpose, a novel virtual screening strategy, with 2D and 3D-QSAR (CoMFA and CoMSIA), data mining, pharmacophore modeling, ADMET prediction, multi-targeted protein-based docking and inverse QSAR, was employed. The 2D-QSAR equations developed for the JAK3, JAK2 and JAK1 involved five physicochemical descriptors. These descriptors correlate with the anti-RA activity with R2 values for JAK3, JAK2 and JAK1 are 0.9811, 0.8620 and 0.9740, respectively. The 3D-QSAR studies such as CoMFA and CoMSIA carried out through PLS analysis of the training set of JAK3, JAK2 and JAK1, gave Q2 values as 0.369, 0.476 and 0.490; \( {\text{R}}_{\text{nev}}^{2} \) values as 0.863, 0.684 and 0.724 and, F values as 23.098, 28.139 and 31.438, respectively. The contour maps produced by the CoMFA and CoMSIA models were used to understand the importance of hydrogen bond donor, acceptor, hydrophobic, steric and electrostatic interactions. The molecular docking studies of these selected compounds with various JAK proteins were carried out and the protein–ligand interactions were also studied. The study concluded that dpp15(s) is a highly potent JAK inhibitor with a very good predicted IC50 value.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Afantitis A, Melagraki G, Sarimveis H et al (2009) A novel QSAR model for predicting the inhibition of CXCR3 receptor by 4-N-aryl-[1,4] diazepane ureas. Eur J Med Chem 44:877–884. doi:10.1016/j.ejmech.2008.05.028
Aswathy L, Jisha RS, Masand VH et al (2016) Computational strategies to explore antimalarial thiazine alkaloid lead compounds based on an Australian marine sponge Plakortis lita. J Biomol Struct Dyn. doi:10.1080/07391102.2016.1220870
Benigni R, Bossa C (2008) Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology. Mutat Res 659:248–261. doi:10.1016/j.mrrev.2008.05.003
Boers M, Verhoeven AC, Markusse HM et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318. doi:10.1016/S0140-6736(97)01300-7
Böhm M, St Rzebecher J, Klebe G (1999) Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem 42:458–477. doi:10.1021/jm981062r
Bringmann G, Rummey C (2003) 3D QSAR investigations on antimalarial naphthylisoquinoline alkaloids by comparative molecular similarity indices analysis (CoMSIA), based on different alignment approaches. J Chem Inf Comput Sci 43:304–316. doi:10.1021/ci025570s
Bush BL, Nachbar RB (1993) Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des 7:587–619. doi:10.1007/BF00124364
Clark M, Cramer RD, Van Opdenbosch N (1989) Validation of the general purpose tripos 5.2 force field. J Comput Chem 10:982–1012. doi:10.1002/jcc.540100804
Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959–5967. doi:10.1021/ja00226a005
Cruciani G, Crivori P, Carrupt P-A, Testa B (2000) Molecular fields in quantitative structure–permeation relationships: the VolSurf approach. J Mol Struct THEOCHEM 503:17–30. doi:10.1016/S0166-1280(99)00360-7
Frank E, Hall M, Trigg L et al (2004) Data mining in bioinformatics using Weka. Bioinformatics 20:2479–2481. doi:10.1093/bioinformatics/bth261
Fridman JS, Scherle PA, Collins R et al (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184:5298–5307. doi:10.4049/jimmunol.0902819
Fujii M, Adachi S, Shimizu T et al (1993) Interstitial lung disease in rheumatoid arthritis: assessment with high-resolution computed tomography. J Thorac Imaging 8:54–62
Gaba S, Jamal S, Drug Discovery Consortium OS, Scaria V (2014) Cheminformatics models for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase. Sci World J 2014:1–9. doi:10.1155/2014/957107
Gabbay E, Tarala R, Will R et al (1997) Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 156:528–535. doi:10.1164/ajrccm.156.2.9609016
Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges. Tetrahedron 36:3219–3228. doi:10.1016/0040-4020(80)801682
Golbraikh A, Tropsha A (2002) Beware of Q2. J Mol Graph Model 20:269–276. doi:10.1016/S1093-3263(01)00123-1
Gonzalez A, Maradit Kremers H, Crowson CS et al (2007) The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 56:3583–3587. doi:10.1002/art.22979
Guner OF, Bowen JP (2013) Pharmacophore modeling for ADME. Curr Top Med Chem 13:1327–1342. doi:10.2174/15680266113139990037
Halgren TA (1996) Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94. J Comput Chem 17:553–586. doi:10.1002/(SICI)1096-987X(199604)17:5/6<553:AID-JCC3>3.0.CO;2-T
Imada K, Leonard WJ (2000) The Jak-STAT pathway. Mol Immunol 37(1–2):1–11. doi:10.1016/S0161-5890(00)00018-3
Irvine JD, Takahashi L, Lockhart K et al (1999) MDCK (Madin–Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:28–33. doi:10.1021/js9803205
Jacobsson LT, Hanson RL, Knowler WC et al (1994) Decreasing incidence and prevalence of rheumatoid arthritis in Pima Indians over a twenty-five-year period. Arthritis Rheum 37:1158–1165. doi:10.1002/art.1780370808
Jamal S, Periwal V, Open Source Drug Discovery Consortium, Scaria V (2013) Predictive modeling of anti-malarial molecules inhibiting apicoplast formation. BMC Bioinform 14:55. doi:10.1186/1471-2105-14-55
Kapelyukh Y, Paine MJI, Maréchal J-D et al (2008) Multiple substrate binding by cytochrome P450 3A4: estimation of the number of bound substrate molecules. Drug Metab Dispos 36:2136–2144. doi:10.1124/dmd.108.021733
Kapetanovic IM (2008) Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact 171:165–176. doi:10.1016/j.cbi.2006.12.006
Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130–4146. doi:10.1021/jm00050a010
Klekota J, Roth FP (2008) Chemical substructures that enrich for biological activity. Bioinformatics 24:2518–2525. doi:10.1093/bioinformatics/btn479
Korzekwa KR, Krishnamachary N, Shou M et al (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137–4147. doi:10.1021/bi9715627
Kroot EJ, de Jong BA, van Leeuwen MA et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835. doi:10.1002/1529-0131(200008)43:8<1831:AID-ANR19>3.0.CO;2-6
Liu K, Feng J, Young SS (2005) PowerMV: a software environment for molecular viewing, descriptor generation, data analysis and hit evaluation. J Chem Inf Model 45:515–522. doi:10.1021/ci049847v
Ma X, Chen C, Yang J (2005) Predictive model of blood–brain barrier penetration of organic compounds. Acta Pharmacol Sin 26:500–512. doi:10.1111/j.1745-7254.2005.00068.x
Masand VH, Rastija V (2017) PyDescriptor: a new PyMOL plugin for calculating thousands of easily understandable molecular descriptors. Chemom Intell Lab Syst 169:12–18. doi:10.1016/j.chemolab.2017.08.003
Milano TR (2010) Chemometrics and QSAR Research Group University of Milano-Bicocca Milano Italy (personal communication)
Miners JO, Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525–538. doi:10.1046/j.1365-2125.1998.00721.x
Orbach H, Gilburd B, Brickman CM et al (2002) Anti-cyclic citrullinated peptide antibodies as a diagnostic test for rheumatoid arthritis and predictor of an erosive disease. Isr Med Assoc J 4:892–893
Pang KS (2009) Safety testing of metabolites: expectations and outcomes. Chem Biol Interact 179:45–59. doi:10.1016/j.cbi.2008.09.013
Patlewicz G, Jeliazkova N, Safford RJ, Worth AP, Aleksiev B (2008) An evaluation of the implementation of the Cramer classification scheme in the Toxtree software. SAR QSAR Environ Res 19(5–6):495–524. doi:10.1080/10629360802083871
Periwal V, Rajappan JK, Open Source Drug Discovery Consortium et al (2011) Predictive models for anti-tubercular molecules using machine learning on high-throughput biological screening datasets. BMC Res Notes 4:504. doi:10.1186/1756-0500-4-504
Plenge RM (2009) Rheumatoid arthritis genetics: 2009 update. Curr Rheumatol Rep 11:351–356. doi:10.1007/s11926-009-0050-0
Ponce YM, Garit JAC, Torrens F et al (2004) Atom, atom-type, and total linear indices of the “molecular pseudograph’s atom adjacency matrix”: application to QSPR/QSAR studies of organic compounds. Molecules 9:1100–1123. doi:10.3390/91201100
Prusis P, Afzelius L (2009) Improvement of site of metabolism predictions for CYP3A4 by using discriminant analysis of compound preference of CYP3A4 X-ray structural conformers and subsequent docking. QSAR Comb Sci 28:865–868. doi:10.1002/qsar.200810182
Rannar S, Lindgren F, Geladi P, Wold S (1994) A PLS kernel algorithm for data sets with many variables and fewer objects. Part 1: theory and algorithm. J Chemom 8:111–125. doi:10.1002/cem.1180080204
Riise T, Jacobsen BK, Gran JT (2000) Incidence and prevalence of rheumatoid arthritis in the county of Troms, northern Norway. J Rheumatol 27:1386–1389
Roy K, Kar S, Ambure P (2015) On a simple approach for determining applicability domain of QSAR models. Chemom Intell Lab Syst 145:22–29. doi:10.1016/j.chemolab.2015.04.013
Sajeev R, Athira RS, Nufail M et al (2013) Computational predictive models for organic semiconductors. J Comput Electron 12:790–795. doi:10.1007/s10825-013-0486-3
Schlichting I (2000) The catalytic pathway of cytochrome P450cam at atomic resolution. Science 287:1615–1622. doi:10.1126/science.287.5458.1615
Scott EE, Halpert JR (2005) Structures of cytochrome P450 3A4. Trends Biochem Sci 30:5–7. doi:10.1016/j.tibs.2004.11.004
Seal A, Passi A, Jaleel UA et al (2012) In-silico predictive mutagenicity model generation using supervised learning approaches. J Cheminform 4:10. doi:10.1186/1758-2946-4-10
Sheridan RP, Korzekwa KR, Torres RA, Walker MJ (2007) Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9. J Med Chem 50:3173–3184. doi:10.1021/jm0613471
Shibi IG, Aswathy L, Jisha RS et al (2015) Molecular docking and QSAR analyses for understanding the antimalarial activity of some 7-substituted-4-aminoquinoline derivatives. Eur J Pharm Sci 77:9–23. doi:10.1016/j.ejps.2015.05.025
Shibi IG, Aswathy L, Jisha RS et al (2016) Virtual screening techniques to probe the antimalarial activity of some traditionally used phytochemicals. Comb Chem High Throughput Screen 19:572–591. doi:10.2174/1386207319666160420141200
Shou M, Grogan J, Mancewicz JA et al (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450–6455
Smith JB, Haynes MK (2002) Rheumatoid arthritis—a molecular understanding. Ann Intern Med 136:908–922. doi:10.7326/0003-4819-136-12-200206180-00012
Smolen JS, Steiner G (2003) Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2:473–488. doi:10.1038/nrd1109
Smolen JS, Aletaha D, Koeller M et al (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370:1861–1874. doi:10.1016/S0140-6736(07)60784-3
Stewart JJP (1993) MOPAC manual, 7th edn, 1993
Strazielle N, Ghersi-Egea J-F (2005) Factors affecting delivery of antiviral drugs to the brain. Rev Med Virol 15:105–133. doi:10.1002/rmv.454
Todeschini R, Gramatica P (1998) New 3D molecular descriptors: the WHIM theory and QAR applications. Perspect Drug Discov 355–380
Toyoshima H, Kusaba T, Yamaguchi M (1993) Cause of death in autopsied RA patients. Ryumachi 33(3):209–214
Trunzer M, Faller B, Zimmerlin A (2009) Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. J Med Chem 52:329–335. doi:10.1021/jm8008663
Vasanthanathan P, Hritz J, Taboureau O et al (2009) Virtual screening and prediction of site of metabolism for cytochrome P450 1A2 ligands. J Chem Inf Model 49:43–52. doi:10.1021/ci800371f
Vinita P, Jinuraj KR, Jaleel UCA, Scaria V (2011) Predictive models for anti-tubercular molecules using machine learning on high-throughput biological screening datasets. BMC Res Notes 4:504. doi:10.1186/1756-0500-4-504
Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein–ligand interactions. Protein Eng 8:127–134. doi:10.1093/protein/8.2.127
Weyand CM, Hicok KC, Conn DL, Goronzy JJ (1992) The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 117:801–806. doi:10.7326/0003-4819-117-10-801
Wildman SA, Crippen GM (1999) Prediction of physicochemical parameters by atomic contributions. J Chem Inf Comput Sci 39:868–873. doi:10.1021/ci990307l
Williams JA, Hyland R, Jones BC et al (2004a) Drug–drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201–1208. doi:10.1124/dmd.104.000794
Williams PA, Cosme J, Vinkovic DM et al (2004b) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683–686. doi:10.1126/science.1099736
Wold S, Sjöström M, Eriksson L (2001) PLS-regression: a basic tool of chemometrics. Chemom Intell Lab Syst 58:109–130. doi:10.1016/S0169-7439(01)00155-1
Yamagishi H, Shirakami S, Nakajima Y et al (2015) Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors. Bioorg Med Chem 23:4846–4859. doi:10.1016/j.bmc.2015.05.028
Yamashita S, Furubayashi T, Kataoka M et al (2000) Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10:195–204. doi:10.1016/S0928-0987(00)00076-2
Yano JK, Wester MR, Schoch GA et al (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091–38094. doi:10.1074/jbc.C400293200
Yee S (1997) In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man—fact or myth. Pharm Res 14:763–766. doi:10.1023/A:1012102522787
Zhao X, Chen M, Huang B et al (2011) Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) studies on α(1A)-adrenergic receptor antagonists based on pharmacophore molecular alignment. Int J Mol Sci 12:7022–7037. doi:10.3390/ijms12107022
Zhou D, Afzelius L, Grimm SW et al (2006) Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions. Drug Metab Dispos 34:976–983. doi:10.1124/dmd.105.008631
Acknowledgements
Jisha, R.S. is thankful to the University of Kerala, Thiruvananthapuram for providing financial assistance in the form of University Junior Research Fellowship for this work. Aswathy L. is thankful to CSIR, New Delhi for the financial assistance in the form of Senior Research Fellowship.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Jisha, R.S., Aswathy, L., Masand, V.H. et al. Exploration of 3,6-dihydroimidazo(4,5-d)pyrrolo(2,3-b)pyridin-2(1H)-one derivatives as JAK inhibitors using various in silico techniques. In Silico Pharmacol. 5, 9 (2017). https://doi.org/10.1007/s40203-017-0029-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40203-017-0029-x